Selecting the best pharmacologic therapy for a patient with type 2 diabetes mellitus (DM) requires choosing between various oral agents, insulins, and combinations of oral agents and insulins. As more oral agents and types of insulins have become available over the past decade, the number of options for single-drug and multidrug therapy has increased progressively. The decision process must factor in the patient’s disease duration, current degree of control, responses to previous pharmacologic regimens, and likelihood of adherence to therapy. The authors of the articles in this supplement to The American Journal of Medicine provide insight into developing a rational approach to selecting and combining oral agents, transitioning from oral therapy to insulin therapy, intensifying insulin therapy, and improving adherence to pharmacologic therapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Medicine
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research.CMAJ. 2004; 171: 735-740
- Gut-derived incretin hormones and new therapeutic approaches.Diabetes Care. 2004; 27: 2554-2559
Klonoff DC. Continuous glucose monitoring: roadmap to 21st century diabetes therapy. Diabetes Care. In press.
- Waiting to inhale.Curr Diab Rep. 2004; 4: 335-341
© 2005 Elsevier Inc. Published by Elsevier Inc. All rights reserved.